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ABSTRACT 
The dry form of ARMD is becoming a serious problem because of the rise in the number of old individuals. 
No effective therapy is available in dry ARMD except for the illusory oral administration of antioxidant 
vitamins. Despite scepticism in the medical community, the therapeutic effect of ozonetherapy had been 
evaluated since 1996. This evaluation has been based on specific biochemical, molecular and 
pharmacological reactions. Nevertheless a number of visual scientists continue to ignore ozonetherapy 
conservatively and prescribe only antioxidant vitamins. Two small clinical studies involving 217 patients 
have been performed at the University of Siena showing that ozonetherapy can stop the progression of the 
disease while improving the visual acuity and the well-being of the patient. Moreover, it seems that 
ozonetherapy is a safe procedure and tends to have an excellent compliance.  
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INTRODUCTION 
This is our fourth report [1-3] regarding the significant 
improvement of visual acuity in patients affected by the 
dry form of age related macular degeneration (ARMD). 
They have been treated twice weekly for several months 
with the autologous infusion of ozonated blood (O3-
Autohemotherapy-O3-AHT). 
During the last few years, this modality of treatment has 
been successfully performed in a number of patients in 
Italy and Germany. Although informed of the results, the 
most of ophthalmologists have remained controversies 
to perform the therapy. Only the dry form of ARMD can 
be treated by ozonetherapy and although it may not 
completely beneficial to increase visual acuity, this 
approach offers a buttress against the natural course of 
ARMD and improves quality of life [1,2]. 
ARMD might be attributed to aging, genetic 
predisposition, smoking, excessive exposure to sunlight, 
a blue iris, hyperopia vascular diseases with hypertension 
and possibly a nutritional lack of zinc and specific 
antioxidants such as lutein. It affects about 25% of 
people over 65 and is associated with a reduction of daily 
activities and independence. There are two forms of 
ARMD: a dry, atrophic form and a wet exudative form 
comprising neovascular formations. The dry form 
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accounts for almost 90% of cases and the pattern of 
clinical features includes drusen, pigment clumping 
and/or retinal pigment epithelium (RPE) alterations and 
geographic atrophy. Patients develop a gradual visual 
loss over a few years with central visual scotomas slowly 
leading to complete loss of vision. The outer face of the 
retina is in contact with the Bruch’s membrane, which 
separates the vascular choroids from the RPE, which 
represents both the histological and functional 
connection with the photoreceptors situated in the outer 
layer. The RPE is vital to the integrity of the 
photoreceptors because it exerts crucial functions such 
as the daily phagocytosis of about 10% of the tips of the 
outer segments of the photoreceptors, the recycling of 
vitamin A and the transfer of oxygen and nutrients from 
the choroids to the photoreceptors and outer retina. The 
macula lutea and in its centre the foveola has the highest 
concentration of cones and is responsible for the visual 
acuity. For its metabolic requirement the foveola 
depends entirely on the choriocapillaris circulation 
because there are no retinal vessels and, among the 
various tissues of the body, it has the highest 
consumption of oxygen of all organs. The lack of oxygen 
rapidly leads to peripheral and/or central loss of vision by 
the degeneration of the neurosensorial cells [4]. Besides 
the critical aspects of ischemia, several deleterious 
processes such as bursts of free radicals, calcium ion 
induced damage and glutamate toxicity aggravate the 
progressive degeneration and loss of precious 
photoreceptors. Indeed there is a good correlation 
between C-Reactive protein serum level and ARMD 
implicating the role of a chronic inflammation and an 
intensive oxidative stress in the pathogenesis of the 
disease [5].  
The wet form of ARMD is characterized by choroidal 
neovascular detachment of the RPE and fibrovascular 
disciform scarring associated with poor visual prognosis. 
The most recent and useful medical treatment is the 
intravitreal administration of monoclonal antibodies, 
particularly the ranibizumab (Lucentis) against the 
vascular endothelial growth factor. O3-AHT cannot be 
used in the wet form because it will accelerate the 
progression of the disease. The therapy is used to stop 
the natural course of the disease or at least to slow it 
down, but it cannot recover lost visual acuity and may 
have disturbing side effects [2]. 
In terms of epidemiological point of view, it must be kept 
in mind that in the UK there are about 250,000 partially 
sighted or blind patients and in the USA almost 10 million 
Americans are blind from ARMD [6]. 
 
HYPOTHESIS 
The anatomic-pathological situation can be dealt by the 
application of ozonetherapy. We have studied this 
problem for over two decades and we have clarified the 
biochemical, molecular and pharmacologic events [7-10]. 
It is interesting to know that ozone is ten-fold more 
soluble in the water of plasma than oxygen: this fact 
implies that mixing human blood with an equivalent 
volume of a gas mixture composed of about 96% O2 and 
4% O3 leads to a very rapid solubilization of ozone, 
which, owing to its reactivity, reacts with hydrosoluble 
antioxidants (ascorbic acid, uric acid, trace of reduced 
glutathione) and with the unsaturated lipids carried out 
by albumin as follows: 
R-CH = HC-R   +   O3   +   H2O → H2O2   +   2 R-CHO 
This means that in 2-3 minutes all the ozone has 
completely reacted and generated its messengers such 
as hydrogen peroxide and aldehydes derived from the 
unsaturated fatty acids peroxidation. The formation of 
aldehydes leads to the final formation of alkenals such as 
trans-4-hydroxy-2-nonenal (4-HNE from n-6) and a small 
quantity of trans-4-hydroxy-2-hexenal (from n-3) [11]. 
Consequently ozone acts simply as a pro-drug and 
generates these two messengers. The unionized 
hydrogen peroxide immediately enters into the mass of 
erythrocytes and activates glycolysis with ATP increase 
and, most important, enhances the production of 2,3 di-
phospho-glygerate (2,3-DPG), which is able to shift to the 
right the oxyhemoglobin dissociation curve, thus 
increasing the release of oxygen in the ischemic areas 
such as the macula lutea and the foveola [12]. 
Although the alkenals are intrinsically toxic, owing to the 
minimal ozone concentration, are produced in the range 
of a few micromoles and undergo to either dilution, 
degradation by specific enzymes, elimination via the bile 
and urine but, most important, submicromolar quantities 
form adducts with either the Cys34 of albumin or the-SH 
group of reduced GSH [9]. This step represents for the 
patient, who has been infused with his or her own 
ozonated blood, a calculated and well tolerated oxidative 
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stress because the albumin adducts transport and deliver 
the alkenals to cells of many organs [13-15]. Alkenals, 
inside the cell, binds to two-SH-groups (Cys272 and 
Cys288) of a large protein denominated Keap-1. Normally 
Keap-1 is bound to Nrf2 and, as many other transcription 
factors, is floating freely in the cell cytoplasm. This 
complex has a half-life of about 20 min because is 
continuously digested by the proteasome. However, 
when the two SH groups of the Keap1 have bound two 
molecules of 4-HNE, the protein Nrf2 is released and 
translocates into the cell nucleus where, after making an 
heterodimer with a small Maf protein, binds to the 
antioxidant response elements (ARE). This is the crucial 
event able to stimulate the upregulation of about 200 
genes responsible for the transcription of a great number 
of antioxidant proteins (SOD, catalase, GSH-Px, GSH-Tr, 
etc) phase II enzymes and heme-oxygenase-1[16-18], 
which is a very protective enzyme. With the progress of 
ozonetherapy, these enzymes will be able to reverse the 
chronic oxidative stress induced by the chronic 
inflammation. At the same time, the enhanced oxygen 
release and possibly of lutein helps to stop the progress 
of ARMD. So far, millions of ozonated autohemotherapy, 
performed with small and precise ozone dosages, have 
never caused any side effects. In fact, most patients 
report a feeling of wellness which is likely due to a 
transitory increase of cortisol [17]. Lastly, ozonetherapy 
has also a minimal cost. 
For the dry ARMD there are no useful therapies with the 
exception of the controversial oral administration of 
antioxidants such as vitamin A, C and E [5] with the 
addition of lutein and zeaxantin [19]. These compounds 
are certainly not harmful but at the best they may only 
delay the progression of the diseases after an average 
treatment period of at least six years, difficult to comply. 
In terms of ozonetherapy procedure, depending upon 
the patient’s body weight, between 150-225 ml of blood 
are drawn by vacuum from an antecubital vein via a 19-
21 G needle into a sterile glass, 500 ml bottle (Ozonosan, 
Iffezheim, Germany) containing 1 ml of 3.8% Na citrate 
solution as an anticoagulant for every 9 ml of withdrawn 
blood (9:1 ratio). A corresponding volume of a gas 
mixture (O2: 96%- O3: 4%), precisely measured regarding 
the ozone concentration via a spectrophotometrically 
reading on line at 253.7 nm (Hartley band), is 
immediately added with an initial ozone concentration of 
20 mcg/ml gas per ml of blood. Thus for a total volume of 
200 ml blood the total ozone dose is equivalent to 4.0 
mg. Ozone is produced by a last generation ozone 
generator fed with only medical oxygen. The 
spectrophotometer must be checked by iodometric 
titration every year according the International ozone 
Association rule. The gas and blood are immediately and 
gently mixed, avoiding foam formation, for no longer 
than a few minutes and then the oxygenated-ozonated 
blood is infused into the donor patient in about 15 
minutes. It is emphasized that the transfusion must be 
only autologous and is absolutely safe. The treatment is 
carried out twice weekly (either Monday and Thursday or 
Tuesday and Friday) for the initial 9-10 weeks. Normally 
the patient starts to note an improvement of visual 
acuity after 4-6 treatments. Afterwards it must be 
performed at least every 10 days for maintaining the 
therapeutic effects. It is important to note that the initial 
low ozone concentration is slowly upgraded up to no 
more than 50 mcg per ml of blood. The axiom: start low, 
go slow is proficiently used with this procedure. Indeed 
the oxidation properties of ozone represent a controlled 
oxidative stress for the patient and the low ozone 
concentrations are well tolerated because they yield a 
hormetic dose-response relationship [10]. The above 
maintenance therapy is absolutely necessary and it can 
last several years. The explanation is due to the fact that 
ozone therapy is based on precise biochemical basis and, 
if it is suspended, the therapeutic effects tend to fade 
and possibly disappear within 6-9 months. The patient 
must be informed that the biochemical reactions have a 
rather short memory but this is not a drawback because 
patients are very compliant once they have noted the 
improvement. Indeed the positive patient’s response is 
the best criterion to show that the therapy is effective. 
 
DISCUSSION 
Two clinical trials have been performed by using 
ozonetherapy. The first was carried out by Bocci and 
Diadori [2] in the Department of ophthalmology of the 
University of Siena from 1996 to 2001 and included 77 
patients. The trial was complicated because the clinical 
committee obliged us to evaluate a control group of 
patients treated with only oxygenated blood therapy. 
Although the request was theoretically correct, during a 
preliminary attempt only a minimal advantage had been 
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noted. Today this request appears unethical because the 
oxygenation improvement is not due to the slow and 
transitory infusion of the hyperoxygenated blood 
because the simply oxygenated blood abundantly mixes 
with venous blood. The patient age ranged from 63 to 81 
years old and each patient was treated for at least two 
years. In the treatment group an improvement in visual 
acuity more that 2 ETDRS lines was observed in 36 
patients (66.6%), equal or less than 2 ETDRS lines in 18 
patients (33.3%). In the control group an improvement in 
visual acuity more than 2 ETDRS lines was observed in 7 
patients (30.4%), equal or less than 2 ETDRS lines in 16 
patients (68.5%) These differences were statistically 
significant (chi-square). Laboratory tests regarding blood 
cells, coagulation tests, fibrinolysis tests, platelet tests, 
plasma proteins and plasma lipids tests either remained 
unvaried or improved. 
The second trial performed by Borrelli et al. [3] enrolled 
140 dry-ARMD patients from 2008 to 2011 with an age 
ranging from 59 to 82 years old. In this trial 70 patients 
underwent ozonetherapy while the control group (70 
patients) assumed only the multivitaminic therapy. 
Ophthalmic examination was recorded for each eye at 
baseline and after 6 and 12 months for both groups. At 6 
and 12 months, ozone treated eyes showed an average 
acuity change of -0.1 and of -0.2 logMar respectively, 
while control group eyes had a change of 0.2 and of 0.3, 
respectively: As far as the best corrected visual acuity 
(BCVA) changes over time, the data are: at 6 months 
none of the eyes treated with ozone had a deterioration 
in BCVA more than 2 lines: At the same interval, 16% of 
the control group eyes had more than 2 lines loss, 25% 
had more than  3 lines loss (P<0.05). As far as line 
improvements, at 6 months 4% of the treated group eyes 
had an improvement of 1 line compared to 0% of the 
control group patients. Again, at 12 months none of the 
treated group eyes showed a line loss more than 2 or 3 
lines in BCVA compared with more than 2 line loss of 40% 
and more than 3 line loss of 38% in the control group 
patients (P<0.05). Moreover the plasma oxidative stress 
was significantly decreased after the treatment 
confirming the role of antioxidants enzymes in the 
increase and the reduction of the oxidative stress. 
Patients reported an improvement of their general 
conditions, particularly in terms of increased efficacy, 
mental concentration and memory as assessed by the 
National Eye Visual Function Questionnaire (NEI-VFQ) 
before and after the end of the study in all patients of 
group 1 and 2 [3]. 
 
CONCLUSION: 
The fascinating aspect of ozonetherapy is its ability to 
trigger a number of defence mechanisms against 
ischemic and neurotoxic injury thus preventing the death 
of photoreceptors. These effects are summarized as 
follows:  
1) Improvement of blood rheology. 
2) Improvement of the glycolytic pathways on 
erythrocytes. The increased concentration of ATP levels 
may facilitate a micro release at hypoxic sites. 
3) Activation of the hexose-monophosphate shunt 
on erythrocytes with increased levels of 2,3-DPG 
particularly if the patient has had a low level. This change 
increases oxygen availability to hypoxic tissues due to a 
shift to the right of the HbO2 dissociation curve. 
4) Vasodilation due to enhanced release of nitric 
oxide and prostacyclin. 
5) Release of growth factors from platelets. 
6) Of great importance is the upregulation of 
antioxidant enzymes, phase 2-proteins and heme-
oxygenase-1 with release of CO and bilirubin. 
The observation that visual acuity improves more rapidly 
in patients with an initial deficit than in almost blind 
patients strongly suggests that patients should be 
encouraged to start ozonetherapy as early as possible. It 
appears obvious that the therapy minimizes the death of 
photoreceptors. Finally there are other retinal 
degenerative disorders such as degenerative myopia, 
retinal vascular disorders due to diabetes, retinitis 
pigmentosa, recessive Stargardt’s disease, ischemic optic 
neuropathies and glaucoma. We would appreciate the 
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